ChromaGenix is expanding its commercial leadership team with two senior appointments that bring decades of experience in bioprocessing and biotechnology. These hires reinforce the company’s commitment to supporting customers worldwide…
Five-year collaboration will focus on novel peptide-based ligands to power future chromatography solutions for gene therapy, vaccines, and advanced biologics The R&D program will develop up to ten new peptide-based…
ChromaGenixTM will combine industry expertise, academic innovation, and $35 million in planned investment to develop and scale next-generation purification technologies for gene therapies, vaccines, and immunotherapies. Newly formed company ChromaGenix…